NEW ZEALAND DATA SHEET

1. PRODUCT NAME
DALACIN® C 600 mg/4 mL solution for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 mL of DALACIN C solution contains 178.22 mg/mL clindamycin phosphate equivalent to 150 mg clindamycin.

Excipients with known effect:
Each 1 mL of solution contains 9.45 mg benzyl alcohol.
For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless, sterile solution.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications
Clindamycin phosphate has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of Gram-positive bacteria such as Streptococci, Staphylococci and Pneumococci:

1. Upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever.
2. Lower respiratory infections including bronchitis, pneumonia, empyema and lung abscess.
3. Skin and soft tissue infections including acne, furuncles, cellulitis, impetigo, abscesses, and wound infections. For specific skin and soft tissue infections like erysipelas and paronychia (panaritium).
4. Bone and joint infections including osteomyelitis and septic arthritis.
5. Pelvic infections including endometritis, cellulitis, vaginal cuff infection tubo-ovarian abscesses salpingitis and pelvic inflammatory disease when given in conjunction with an antibiotic of appropriate Gram-negative aerobic spectrum. In cases of cervicitis due to Chlamydia trachomatis, monotherapy with clindamycin has been shown to be effective in eradicating the organism.
6. Intra-abdominal infections including peritonitis and abdominal abscess when given in conjunction with an antibiotic of appropriate Gram-negative aerobic spectrum.
7. Septicaemia and endocarditis - the effectiveness of clindamycin in the treatment of selected cases of endocarditis has been documented when clindamycin is determined to be bactericidal to the infecting organism by \textit{in vitro} testing of appropriate achievable serum concentrations.

8. Dental infections such as periodontal abscess and periodontitis.

9. Toxoplasmic encephalitis in patients with AIDS. In patients who are intolerant to conventional treatment, clindamycin in combination with pyrimethamine has been shown to be efficacious.

10. \textit{Pneumocystis jirovecii} pneumonia in patients with AIDS. In patients who are intolerant to or do not respond to conventional treatment, clindamycin in combination with primaquine has been shown to be efficacious.

\textbf{4.2 Dose and method of administration}

\textbf{Dose}

DALACIN C IM administration should be used undiluted.

DALACIN C IV administration should be diluted (see Dilution for IV use and IV infusion rates below).

If significant diarrhoea occurs during therapy, this antibiotic should be discontinued (see section 4.4).

\textbf{Adults:} Serious Infections: 150 mg – 300 mg every six hours.

More severe infections: 300 mg – 450 mg every six hours.

\textbf{Children:} Clindamycin should be dosed based on total body weight regardless of obesity. The maximum daily dose in obese children should not exceed the adult dose.

Serious Infections: 8 – 16 mg/kg/day divided into three or four equal doses.

More severe infections: 16 – 25 mg/kg/day divided into three or four equal doses.

\textbf{For the treatment of Pelvic Inflammatory Disease - Inpatient treatment}

Clindamycin phosphate 900 mg (IV) q8h daily plus an antibiotic with an appropriate Gram-negative aerobic spectrum administered IV; e.g. gentamicin in patients with normal renal function. Continue (IV) drugs for at least 4 days and at least 48 hours after the patient improves. Then continue oral clindamycin hydrochloride 450 mg q6h daily to complete 10-14 days total therapy.

\textbf{For the treatment of Cervicitis due to Chlamydia trachomatis:}

Clindamycin hydrochloride by mouth 450 mg 4 times daily for 10-14 days.

\textbf{For the treatment of \textit{β}-haemolytic Streptococcal infections}

In cases of \textit{β}-haemolytic Streptococcal infections, treatment should continue for at least ten days.
For the treatment of Toxoplasmic encephalitis in patients with AIDS

Clindamycin phosphate IV or clindamycin hydrochloride by mouth 600-1200 mg every 6 hours for two weeks followed by 300-600 mg by mouth every 6 hours. The usual total duration of therapy is 8 to 10 weeks. The dose of pyrimethamine is 25-75 mg by mouth daily for 8-10 weeks. Folinic acid 10-20 mg/day should be given with higher doses of pyrimethamine.

For the treatment of *Pneumocystis jirovecii* pneumonia in patients with AIDS

Clindamycin phosphate IV 600-900 mg every 6 hours or 900 mg IV every 8 hours or clindamycin hydrochloride 300-450 mg by mouth every 6 hours for 21 days. Primaquine 15-30 mg dose by mouth once daily for 21 days.

**Method of administration**

**Dilution for IV Use and IV Infusion Rates**

DALACIN C must be diluted prior to IV administration. The concentration of clindamycin in diluent for infusion should not exceed 18 mg per mL AND INFUSED AT A RATE OF NOT MORE THAN 30 MG PER MINUTE AS INDICATED BELOW:

When necessary, pH is adjusted with sodium hydroxide and/or hydrochloric acid.

**Table 1. Dilution and Infusion Rates in Relation to Total Infusion Dose**

<table>
<thead>
<tr>
<th>Dose</th>
<th>Diluent</th>
<th>Minimum Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>300 mg</td>
<td>50 mL</td>
<td>10 min</td>
</tr>
<tr>
<td>600 mg</td>
<td>50 mL</td>
<td>20 min</td>
</tr>
<tr>
<td>900 mg</td>
<td>50-100 mL</td>
<td>30 min</td>
</tr>
<tr>
<td>1200 mg</td>
<td>100 mL</td>
<td>40 min</td>
</tr>
</tbody>
</table>

Administration of more than 1200 mg in a single 1-hour infusion is not recommended.

**Directions for use**

The neck of the ampoule is pre-scored at the point of constriction. No ampoule file is needed to open the ampoules. A coloured dot on the ampoule head helps to orientate the ampoule. Take the ampoule and face the coloured dot. The ampoule opens easily by placing the thumb on the coloured dot and gently pressing downwards.

**4.3 Contraindications**

This drug is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin, lincomycin or any of the ingredients listed under section 6.1.

**4.4 Special warnings and precautions for use**

SERIOUS ANAPHYLACTOID REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH ADRENALINE. OXYGEN, COLLOID INFUSION, ANTIHISTAMINES AND INTRAVENOUS CORTICOSTEROIDS SHOULD ALSO BE ADMINISTERED AS INDICATED.
Severe hypersensitivity reactions, including severe skin reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalised exanthematous pustulosis (AGEP) have been reported in patients receiving clindamycin therapy. If a hypersensitivity or severe skin reaction occurs, clindamycin should be discontinued and appropriate therapy should be initiated (see section 4.3 and section 4.8).

This product contains benzyl alcohol which is associated with severe adverse effects, including fatal "gasperg syndrome", in paediatric patients. The minimum amount of benzyl alcohol at which toxicity may occur is unknown. The risk of benzyl alcohol toxicity depends on the quantity administered and the liver and kidneys' capacity to detoxify the chemical. Premature and low birth weight infants may be more likely to develop toxicity.

The use of clindamycin can lead to the development of severe colitis. Fatalities have been reported. Therefore, DALACIN C should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in section 4.1. It should not be used in patients with non-bacterial infections such as most upper respiratory tract infections.

A toxin produced by Clostridoides difficile appears to be the primary cause. The severity of the colitis may range from mild to life threatening. It is important to consider this diagnosis in patients who develop diarrhoea or colitis in association with the use of antibiotics, including parenteral clindamycin. Symptoms may occur up to several weeks after cessation of antibiotic therapy. Cholestyramine and colestipol resins have been shown to bind the toxin in vitro. The colitis is usually characterised by mild watery diarrhoea to severe, persistent diarrhoea, leukocytosis, fever, severe abdominal cramps which may be associated with the passage of blood and mucous and if allowed to progress may produce peritonitis, shock and toxic megacolon. Endoscopic examination may reveal pseudomembranous colitis.

Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone, however in moderate to severe cases appropriate therapy with suitable oral antibacterial agents effective against C. difficile should be considered. Fluids, electrolytes and protein replacement should be provided when indicated.

When significant diarrhoea occurs, the drug should be discontinued or, if necessary, continued only with close observation of the patient. Large bowel endoscopy has been recommended.

Vancomycin has been found to be effective in the treatment of antibiotic associated pseudomembranous colitis produced by C. difficile. The usual adult dose is 500 mg to 2 g of vancomycin orally per day in three to four divided doses administered for seven to ten days.

If both a resin and vancomycin are to be administered concurrently, it may be advisable to separate the time of administration of each drug.

Diarrhoea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of therapy with clindamycin.

Systemic corticoids and corticoid retention enemas may help relieve the colitis. Other causes of colitis should also be considered.

A careful inquiry should be made concerning previous sensitivities to medicines and other allergens.
Antibiotic-associated colitis and diarrhoea (due to *C. difficile*), occur more frequently and may be more severe in debilitated and/or elderly patients (> 60 years). When clindamycin is indicated in these patients, they should be carefully monitored for change in bowel frequency.

*C. difficile* associated diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin, and may range in severity from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*. 

*C. difficile* produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

DALACIN C should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.

DALACIN C should be prescribed with caution in atopic individuals.

During prolonged therapy periodic liver function tests and blood counts should be performed.

Clindamycin is potentially nephrotoxic. Acute kidney injury including acute renal failure has been reported. Therefore, monitoring of renal function should be considered during therapy of patients with pre-existing renal dysfunction or taking concomitant nephrotoxic drugs and monitoring of renal function should be performed if therapy is prolonged.

Patients with very severe renal disease and/or very severe hepatic disease accompanied by severe, metabolic aberrations should be dosed with caution, and serum clindamycin levels monitored during high-dose therapy.

Indicated surgical procedures should be performed in conjunction with antibiotic therapy. The use of DALACIN C may result in overgrowth of non-susceptible organisms - particularly yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

DALACIN C should not be injected intravenously undiluted as a bolus, but should be infused over at least 10-60 minutes as directed in the DOSAGE AND ADMINISTRATION section.

Drugs which delay peristalsis (e.g. opiates and diphenoxylate with atropine [LOMOTIL®]) may prolong and/or worsen the condition and should not be used.

DALACIN C should be used with caution in patients with a history of regional enteritis, ulcerative colitis or antibiotic associated colitis.

Stool culture for *C. difficile* and stool assay for *C. difficile* toxin maybe helpful diagnostically.

Rare instances of cardiopulmonary arrest and hypotension have been reported following too rapid intravenous administration (see section 4.2).

Local irritation, pain, induration and sterile abscess have been reported after intramuscular injection and thrombophlebitis after intravenous infusion (see section 4.8). Reactions can be
minimised by giving deep intramuscular injections and avoiding prolonged use of indwelling intravenous catheters.

**Usage in the newborn and infants**

When DALACIN C is administered to newborns and infants, appropriate monitoring of organ system functions is desirable.

**Usage in meningitis**

Since clindamycin does not diffuse adequately into the cerebrospinal fluid, the drug should not be used in the treatment of meningitis.

### 4.5 Interaction with other medicines and other forms of interaction

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.

Clindamycin is metabolised predominantly by CYP3A4, and to a lesser extent by CYP3A5, to the major metabolite clindamycin sulfoxide and minor metabolite N-desmethyleclindamycin. Therefore, inhibitors of CYP3A4 and CYP3A5 may reduce clindamycin clearance and inducers of these isoenzymes may increase clindamycin clearance. In the presence of strong CYP3A4 inducers such as rifampicin, monitor for loss of effectiveness.

*In vitro* studies indicate that clindamycin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2E1 or CYP2D6 and only moderately inhibits CYP3A4. Therefore, clinically important interactions between clindamycin and co-administered drugs metabolised by these CYP enzymes are unlikely.

### 4.6 Fertility, pregnancy and lactation

**Pregnancy - Category A**

Clindamycin crosses the placenta in humans. After multiple doses, amniotic fluid concentrations were approximately 30% of maternal concentrations. Clindamycin should be used in pregnancy only if clearly needed.

Benzyl alcohol can cross the placenta (see section 4.4).

**Breast-feeding**

Clindamycin has been reported to appear in human breast milk in ranges from <0.5 to 3.8 micrograms/mL. Clindamycin has the potential to cause adverse effects on the breastfed infant’s gastrointestinal flora such as diarrhoea or blood in the stool, or rash. Therefore, clindamycin is not recommended for nursing mothers.

If oral or intravenous clindamycin is required by a nursing mother, it is not a reason to discontinue breastfeeding, but an alternate drug may be preferred. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for clindamycin and any potential adverse effects on the breastfed child from clindamycin or from the underlying maternal condition.
4.7 Effects on ability to drive and use machines

The effect of clindamycin on the ability to drive or operate machinery has not been systematically evaluated.

4.8 Undesirable effects

The adverse effects listed in the table below are presented by system organ class. Within each frequency category, the adverse effects are presented in the order of frequency and then by decreasing medical seriousness.

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Common (≥ 1/100 to &lt; 1/10)</th>
<th>Uncommon (≥1/1000 to &lt;1/100)</th>
<th>Rare (≥1/10000 to &lt;1/1000)</th>
<th>Frequency not known (cannot be estimated from available data)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>Pseudomembranous colitis</td>
<td></td>
<td>Vaginal infection</td>
<td></td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Eosinophilia</td>
<td></td>
<td>Agranulocytosis, neutropenia, thrombocytopenia, leucopenia</td>
<td></td>
</tr>
<tr>
<td>Immune system disorders</td>
<td></td>
<td></td>
<td>Anaphylactoid reaction</td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td>Dysgeusia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td></td>
<td>Cardiorespiratory arrest§†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Thrombophlebitis†</td>
<td>Hypotension§†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Diarrhoea, abdominal pain</td>
<td>Vomiting, nausea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td></td>
<td></td>
<td>Jaundice</td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Rash maculo-papular</td>
<td>Urticaria</td>
<td>Erythema multiforme, pruritus</td>
<td>Toxic epidermal necrolysis (TEN), Steven Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalised exanthematous pustulosis (AGEP), dermatitis exfoliative, dermatitis bullous, rash morbilliform</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
<td></td>
<td></td>
<td>Polyarthritis</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
<td>Pain†, injection site abscess†</td>
<td>Injection site irritation†</td>
<td></td>
</tr>
<tr>
<td>Investigations</td>
<td>Liver function test abnormal</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CIOMS III categories: Very Common ≥1/10 (≥10%); Common ≥1/100 to <1/10 (≥1% and <10%); Uncommon ≥1/1000 to <1/100 (≥0.1% and <1%); Rare ≥1/10,000 to <1/1000 (≥0.01% and <0.1%); Very Rare <1/10,000
<table>
<thead>
<tr>
<th>System organ class</th>
<th>Common (≥ 1/100 to &lt; 1/10)</th>
<th>Uncommon (≥1/1000 to &lt;1/100)</th>
<th>Rare (≥1/10000 to &lt;1/1000)</th>
<th>Frequency not known (cannot be estimated from available data)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(&lt;0.01%)</td>
<td></td>
<td></td>
<td></td>
<td>§ Rare instances have been reported following too rapid intravenous administration (see section 4.2).</td>
</tr>
</tbody>
</table>

† Adverse reactions apply only to injectable formulations.

**Post-Marketing Experience**

The following additional adverse reactions have been reported during post-marketing experience.

**Infections and infestations**

Frequency not known: *C. difficile* colitis.

**Immune system disorders**

Frequency not known: Anaphylactic shock, anaphylactic reaction, hypersensitivity.

**Skin and subcutaneous tissue disorders**

Frequency not known: Angioedema.

**Renal and urinary disorders**

Frequency not known: Acute kidney injury.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/).

**4.9 Overdose**

The minimal toxic or lethal dose is not well established. At therapeutic doses, the primary toxic effects may involve the gastrointestinal tract and may include severe diarrhoea and pseudomembranous colitis that may result in death. Rapid administration of large doses has resulted in ventricular dysrhythmias, hypotension and cardiac arrest. Dermatitis, nephrotoxicity, hepatotoxicity, and various haematological abnormalities are toxic effects that occur less frequently.

No specific antidote is known. Support respiratory and cardiac function. In cases of overdose, drug levels of clindamycin are not clinically useful. However, monitoring serum concentrations in patients with markedly reduced renal and hepatic function, may be indicated during high-dose therapy. Monitor full blood count in patients with significant exposure as clindamycin may produce abnormalities of the haematopoietic system. Because clindamycin may cause hepatotoxicity, monitor liver function tests in patients with significant exposure.

Neither haemodialysis nor peritoneal dialysis appear to be effective in reducing clindamycin levels significantly.
Serious anaphylactoid reactions require immediate emergency treatment with adrenaline. Oxygen and intravenous corticosteroids should also be administered as indicated.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamics effects

Mechanism of action
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis. It binds to the 50S ribosomal subunit and affects both ribosome assembly and the translation process. Although clindamycin phosphate is inactive \textit{in vitro}, rapid \textit{in vivo} hydrolysis converts this compound to the antibacterially active clindamycin. At usual doses, clindamycin exhibits bacteriostatic activity \textit{in vitro}.

Pharmacodynamic effects
Efficacy is related to the time period over which the agent level is above the minimum inhibitory concentration (MIC) of the pathogen (%T/MIC).

Resistance
Resistance to clindamycin is most often due to mutations at the rRNA antibiotic binding site or methylation of specific nucleotides in the 23S RNA of the 50S ribosomal subunit. These alterations can determine \textit{in vitro} cross resistance to macrolides and streptogramins B (MLS\textsubscript{B} phenotype). Resistance is occasionally due to alterations in ribosomal proteins. Resistance to clindamycin may be inducible by macrolides in macrolide-resistant bacterial isolates. Inducible resistance can be demonstrated with a disk test (D-zone test) or in broth. Less frequently encountered resistance mechanisms involve modification of the antibiotic and active efflux. There is complete cross resistance between clindamycin and lincomycin. As with many antibiotics, the incidence of resistance varies with the bacterial species and the geographical area. The incidence of resistance to clindamycin is higher among methicillin-resistant Staphylococcal isolates and penicillin-resistant Pneumococcal isolates than among organisms susceptible to these agents.

Antimicrobial activity
Although clindamycin phosphate is inactive \textit{in vitro}, rapid \textit{in vivo} hydrolysis converts this compound to the antibacterially active clindamycin.

Clindamycin has been shown to have \textit{in vitro} activity against most isolates of the following organisms:

Aerobic bacteria

Gram-positive bacteria:

- \textit{Staphylococcus aureus} (methicillin-susceptible isolates)
- Coagulase-negative Staphylococci (methicillin-susceptible isolates)
- \textit{Streptococcus pneumoniae} (penicillin-susceptible isolates)
- Streptococci groups A, B, C, and G
Viridans group Streptococci
*Corynebacterium* spp.

Atypical bacteria:
*Chlamydia trachomatis*

Anaerobic bacteria

Gram-negative bacteria:
*Bacteroides* spp.
*Fusobacterium* spp.
*Gardnerella vaginalis*
*Prevotella* spp.

Gram-positive bacteria:
*Propionibacterium acnes*
*Actinomyces* spp.
*Eggerthella (Eubacterium)* spp.
*Peptococcus* spp.
*Peptostreptococcus* spp. (*Finegoldia magna, Micromonas micros*)
*Clostridioides* spp. (except *C. difficile*)

Fungi
*Pneumocystis jirovecii*

Protozoans
*Toxoplasma gondii*
*Plasmodium falciparum*

**Breakpoints**

Dilution or diffusion techniques – either quantitative (MIC) or breakpoint, should be used following a regularly updated, recognised and standardised method (e.g. CLSI or EUCAST). Standardised susceptibility testing procedures require the use of laboratory control microorganisms to control the technical aspects of laboratory procedures.

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable. Particularly in severe infections or therapy failure microbiological diagnosis with verification of the pathogen and its susceptibility to clindamycin is recommended.

Resistance is usually defined by susceptibility interpretive criteria (breakpoints) established by Clinical and Laboratory Standards Institute (CLSI) or European Committee on Antimicrobial Susceptibility Testing (EUCAST) for systemically administered antibiotics.

Clinical and Laboratory Standards Institute (CLSI) breakpoints for relevant organisms are listed below.
### Table 2. CLSI Susceptibility Interpretive Criteria for Clindamycin

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Minimal Inhibitory Concentrations (mcg/mL)</th>
<th>Disk Diffusion (Zone Diameters in mm)&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S</td>
<td>I</td>
</tr>
<tr>
<td><strong>Staphylococcus spp.</strong></td>
<td>≤0.5</td>
<td>1–2</td>
</tr>
<tr>
<td><strong>Streptococcus spp.</strong></td>
<td>≤0.25</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>Anaerobic bacteria</strong>&lt;sup&gt;b&lt;/sup&gt;</td>
<td>≤2</td>
<td>4</td>
</tr>
</tbody>
</table>

NA=not applicable; S=susceptible; I=intermediate; R=resistant.

<sup>a</sup>Disk content 2 micrograms of clindamycin

<sup>b</sup>MIC ranges for anaerobes are based on agar dilution methodology.

A report of “Susceptible” (S) indicates that the pathogen is likely to be inhibited if the antimiicrobial compound in the blood reaches the concentrations usually achievable. A report of “Intermediate” (I) indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where high dosage of drug can be used. This category also provides a buffer zone, which prevents small, uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” (R) indicates that the pathogen is not likely to be inhibited if the antimiicrobial compound in the blood reaches the usually achievable concentrations other therapy should be selected.

Standardised susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test. Standard clindamycin powder should provide the MIC ranges in Table 3. For the disk diffusion technique using the 2 mcg clindamycin disk the criteria provided in Table 3 should be achieved.

### Table 3. CLSI Acceptable Quality Control (QC) Ranges for Clindamycin to be Used in Validation of Susceptibility Test Results

<table>
<thead>
<tr>
<th>QC Strain</th>
<th>Minimum Inhibitory Concentration Range (mcg/mL)</th>
<th>Disk Diffusion Range (Zone Diameters in mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Staphylococcus aureus ATCC 29213</strong></td>
<td>0.06–0.25</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Staphylococcus aureus ATCC 25923</strong></td>
<td>NA</td>
<td>24–30</td>
</tr>
<tr>
<td><strong>Streptococcus pneumoniae ATCC 49619</strong></td>
<td>0.03–0.12</td>
<td>19–25</td>
</tr>
<tr>
<td><strong>Bacteroides fragilis ATCC 25285</strong></td>
<td>0.5–2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Bacteroides thetaiotaomicron ATCC 29741</strong></td>
<td>2–8&lt;sup&gt;a&lt;/sup&gt;</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Eggerthella lenta ATCC 43055</strong></td>
<td>0.06–0.25&lt;sup&gt;a&lt;/sup&gt;</td>
<td>NA</td>
</tr>
</tbody>
</table>

NA=Not applicable.

ATCC® is a registered trademark of the American Type Culture Collection

<sup>a</sup>MIC ranges for anaerobes are based on agar dilution methodology.

The European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints are presented below.
Table 4. EUCAST Susceptibility Interpretive Criteria for Clindamycin

<table>
<thead>
<tr>
<th>Organism</th>
<th>MIC breakpoints (mg/L)</th>
<th>Zone diameter breakpoints (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S ≤</td>
<td>R &gt;</td>
</tr>
<tr>
<td>Staphylococcus spp.</td>
<td>0.25</td>
<td>0.5</td>
</tr>
<tr>
<td>Streptococcus Groups A, B, C and G</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Streptococcus pneumoniae</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Viridans group Streptococci</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Gram-positive anaerobes</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Gram-negative anaerobes</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Corynebacterium spp.</td>
<td>0.5</td>
<td>0.5</td>
</tr>
</tbody>
</table>

*Disk content 2 µg of clindamycin
NA=not applicable; S=susceptible; R=resistant

EUCAST QC ranges for MIC and disk zone determinations are in the table below.

Table 5. EUCAST Acceptable Quality Control (QC) Ranges for Clindamycin to be Used in Validation of Susceptibility Test Results

<table>
<thead>
<tr>
<th>QC Strain</th>
<th>Minimum Inhibitory Concentration Range (mcg/mL)</th>
<th>Disk Diffusion Range (Zone Diameters in mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Staphylococcus aureus</em> ATCC 29213</td>
<td>0.06–0.25</td>
<td>23-29</td>
</tr>
<tr>
<td><em>Streptococcus pneumoniae</em> ATCC 49619</td>
<td>0.03–0.125</td>
<td>22-28</td>
</tr>
</tbody>
</table>

ATCC® is a registered trademark of the American Type Culture Collection

5.2 Pharmacokinetic properties

Biologically inactive clindamycin phosphate is rapidly converted to active clindamycin.

By the end of short-term intravenous infusion, peak serum levels of active clindamycin are reached.

*In vitro* studies in human liver and intestinal microsomes indicated that clindamycin is predominantly oxidised by CYP3A4, with minor contribution from CYP3A5, to form clindamycin sulfoxide and a minor metabolite, N-desmethylclindamycin.

Biologically-inactive clindamycin phosphate disappears rapidly from the serum, the average disappearance half-life is 6 minutes; however, the serum disappearance half-life of active clindamycin is about 3 hours in adults and 2.5 hours in children.

After intramuscular injection of DALACIN C, peak levels of active clindamycin are reached within 3 hours in adults and 1 hour in children. Serum level curves may be constructed from IV peak serum levels as given in Table 6 by application of the disappearance half-lives listed above.

Serum levels of clindamycin can be maintained above the *in vitro* minimum inhibitory concentrations for most indicated organisms by administration of DALACIN C every 8-12 hours in adults and every 6-8 hours in children, or by continuous intravenous infusion. An equilibrium state is reached by the third dose.
The disappearance half-life of clindamycin is increased slightly in patients with markedly reduced renal or hepatic function; dosage schedules need not be modified in the presence of mild to moderate renal or hepatic disease. No significant levels of clindamycin are attained in the cerebrospinal fluid even in the presence of inflamed meninges.

Serum assays for active clindamycin require an inhibitor to prevent in vitro hydrolysis of clindamycin phosphate.

Table 6: Average Peak Serum Concentrations after Dosing with DALACIN® C Phosphate

<table>
<thead>
<tr>
<th>Dosage Regimen</th>
<th>Clindamycin (micrograms/mL)</th>
<th>Clindamycin Phosphate (micrograms/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy Adult Males (Post Equilibrium)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>300 mg IV in 10 min q 8h</td>
<td>7</td>
<td>15</td>
</tr>
<tr>
<td>600 mg IV in 20 min q 8h</td>
<td>10</td>
<td>23</td>
</tr>
<tr>
<td>900 mg IV in 30 min q 12h</td>
<td>11</td>
<td>29</td>
</tr>
<tr>
<td>1200 mg IV in 45 min q 12h</td>
<td>14</td>
<td>49</td>
</tr>
<tr>
<td>300 mg IM q 8h</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>600 mg IM q 12h*</td>
<td>9</td>
<td>3</td>
</tr>
<tr>
<td>Children (first dose)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-7 mg/kg in 1 h</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>3-5 mg/kg IM</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>5-7 mg/kg IM</td>
<td>8</td>
<td></td>
</tr>
</tbody>
</table>

*Data in this group from patients being treated for infection

Obese paediatric patients aged 2 to less than 18 years

An analysis of pharmacokinetic data in obese paediatric patients aged 2 to less than 18 years demonstrated that clindamycin clearance and volume of distribution normalized by total body weight are comparable regardless of obesity.

5.3 Preclinical safety data

None stated.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Benzyl alcohol (9.45 mg)
Disodium edetate (0.5 mg)
Water for Injections.
6.2 Incompatibilities

DALACIN C has been known to be physically and chemically compatible for at least 24 hours in glucose 5% water and sodium chloride injection solutions containing the following antibiotics in usually administered concentrations:

amikacin sulfate, aztreonam, cefamandole nafate, cefazolin sodium, cefotaxime sodium, cefoxitin sodium, ceftazidime sodium, ceftizoxime sodium, gentamicin sulfate, netilmicin sulfate, piperacillin and tobramycin.

The compatibility and duration of stability of drug mixtures will vary depending on concentration and other conditions.

No incompatibility has been demonstrated with the antibiotics cefalotin, kanamycin, gentamicin, penicillin or carbenicillin.

The following drugs are physically incompatible with DALACIN C:

ampicillin, phenytoin sodium, barbiturates, aminophylline, calcium gluconate, magnesium sulfate, ceftriaxone sodium and ciprofloxacin.

6.3 Shelf life

24 months

6.4 Special precautions for storage

Store at 2°C to 8°C (Refrigerate. Do not freeze)

6.5 Nature and contents of container

4 mL Ampoule (600 mg) is supplied in packs of 1 or 10 ampoules

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

None stated.

7. MEDICINE SCHEDULE

Prescription medicine.

8. SPONSOR

Pfizer New Zealand Ltd
PO Box 3998
Auckland, New Zealand

Toll Free number: 0800 736 363
9. DATE OF FIRST APPROVAL
12 July 1974

10. DATE OF REVISION OF THE TEXT
20 January 2022

® Registered Trademark

Summary table of changes

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.2, 5.2</td>
<td>To add new information regarding PK and PD data for clindamycin in obese children.</td>
</tr>
<tr>
<td>4.4</td>
<td>Minor editorial changes.</td>
</tr>
<tr>
<td>6.5</td>
<td>Amended to include 10s pack size. Removed reference to oral dosage form.</td>
</tr>
</tbody>
</table>